SavedAdd your journal

Journals / Turkish Journal of Pharmaceutical Sciences / 2022 / Cilt: 19 - Sayı: 1

Multi-drug Treatment for COVID-19-induced Acute Respiratory Distress Syndrome

COVID-19 Kaynaklı Akut Solunum Sıkıntısı Sendromu için Çoklu İlaç Tedavisi

Masashi OHE
Pages
101–103
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Considering anti-inflammatory and immunomodulatory effects of the aforementioned drugs and corticosteroids, early treatment with doxycycline, azithromycin, IVM, and corticosteroids is thought to be the most promising option for combating COVID-19-induced ARDS.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Coronavirus disease-2019 (COVID-19), caused by severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2), broke out in late 2019 to become a serious global threat to human health.
📊
Key Findings & Data:In the absence of specific treatments for COVID-19, treatment options are being examined.
💡
Conclusion & Impact:Considering anti-inflammatory and immunomodulatory effects of the aforementioned drugs and corticosteroids, early treatment with doxycycline, azithromycin, IVM, and corticosteroids is thought to be the most promising option for combating COVID-19-induced ARDS.
🔬Design:Research Article
📍Scope:2019 Verileri
⚙️Variables:Domain Parameters

Abstract

Coronavirus disease-2019 (COVID-19), caused by severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2), broke out in late 2019 to become a serious global threat to human health. In the absence of specific treatments for COVID-19, treatment options are being examined. Recently, the anti-SARS-CoV-2 activities of tetracyclines, macrolide antibiotics, and ivermectin (IVM), have attracted considerable attention for their potential as a single or multi-drug treatment regimen. Moreover, tetracyclines, macrolide antibiotics, and IVM possess anti-inflammatory and immunomodulatory effects to reduce the production of cytokines. COVID-19 is characterized by early exponential viral replication, cytokine storm-associated organ damage, including acute respiratory distress syndrome (ARDS) and thrombosis. Considering anti-inflammatory and immunomodulatory effects of the aforementioned drugs and corticosteroids, early treatment with doxycycline, azithromycin, IVM, and corticosteroids is thought to be the most promising option for combating COVID-19-induced ARDS.

Özet

Şiddetli akut solunum yolu sendromu-koronavirüs-2’nin (SARS-CoV-2) neden olduğu Koronavirüs hastalığı-2019 (COVID-19), 2019’un sonlarında patlak vererek insan sağlığı için ciddi bir küresel tehdit haline gelmiştir. COVID-19 için spesifik tedavilerin yokluğunda tedavi seçenekleri inceleniyor. Son zamanlarda, tetrasiklinlerin, makrolid antibiyotiklerin ve ivermektinin (IVM) anti-SARS-CoV-2 aktiviteleri, tek veya çoklu ilaç tedavi rejimi olarak potansiyelleri nedeniyle büyük ilgi görmüştür. Dahası, tetrasiklinler, makrolid antibiyotikler ve IVM sitokin üretimini azaltmak için anti-inflamatuar ve immünomodülatör etkilere sahiptir. COVID-19, erken üstel viral replikasyon, akut solunum sıkıntısı sendromu (ARDS) ve tromboz dahil sitokin fırtınası ile ilişkili organ hasarı ile karakterizedir. Bahsi geçen ilaçların ve kortikosteroidlerin antiinflamatuar ve immünomodülatör etkileri göz önüne alındığında, doksisiklin, azitromisin, IVMve kortikosteroidlerle erken tedavinin, COVID-19 kaynaklı ARDS ile mücadelede en umut verici seçenek olduğu düşünülmektedir.

🔖

Cite This Article

OHE, M. (2022). Multi-drug Treatment for COVID-19-induced Acute Respiratory Distress Syndrome. Turkish Journal of Pharmaceutical Sciences, Cilt: 19 - Sayı: 1, 101–103. https://ajindex.com/articles/613604

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (10)

  1. Bernardino AL, Kaushal D, Philipp MT. The antibiotics doxycycline and minocycline inhibit the inflammatory responses to the Lyme disease spirochete Borrelia burgdorferi. J Infect Dis. 2009;199:1379-1388
  2. Zimmermann P, Ziesenitz VC, Curtis N, Ritz N. The Immunomodulatory effects of macrolides-a systematic review of the underlying mechanisms. Front Immunol. 2018;9:302
  3. Zhang X, Song Y, Ci X, An N, Ju Y, Li H, Wang X, Han C, Cui J, Deng X. Ivermectin inhibits LPS-induced production of inflammatory cytokines and improves LPS-induced survival in mice. Inflamm Res. 2008;57:524- 529
  4. Gironi LC, Damiani G, Zavattaro E, Pacifico A, Santus P, Pigatto PDM, Cremona O, Savoia P. Tetracyclines in COVID-19 patients quarantined at home: literature evidence supporting real-world data from a multicenter observational study targeting inflammatory and infectious dermatoses. Dermatol Ther. 2021;34:e14694
  5. Tsiakos K, Tsakiris A, Tsibris G, Voutsinas P, Panagopoulos P, Kosmidou M, Petrakis V, Gravvani A, Gkavogianni T, Klouras E, Katrini K, Koufargyris P, Rapti I, Karageorgos A, Vrenzos E, Damoulari C, Zarkada V, Sidiropoulou C, Artemi S, Ioannidis A, Papapostolou A, Michelakis E, Georgiopoulou M, Myrodia DM, Tsiamalos P, Syrigos K, Chrysos G, Nitsotolis T, Milionis H, Poulakou G, Giamarellos-Bourboulis EJ. Oral clarithromycin in COVID-19 of moderate severity: the ACHIEVE open label trial using concurrent matched comparators medRxiv. doi: 10.1101/2020.12.22.20248753
  6. Ahmed S, Karim MM, Ross AG, Hossain MS, Clemens JD, Sumiya MK, Phru CS, Rahman M, Zaman K, Somani J, Yasmin R, Hasnat MA, Kabir A, Aziz AB, Khan WA. A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness. Int J Infect Dis. 2021;103:214-216
  7. Alam MT, Murshed R, Bhiuyan E, Saber S, Alam RF, Robin RC. A case series of 100 COVID-19 positive patients treated with combination of ivermectin and doxycycline. Bangladesh Coll Phys Surg. 2020;38(Supplement Issue):10-15
  8. Prasad A. Early administration of ivermectin, azithromycin & doxycycline along with i.v. prednisolone in a case of COVID -19 disease may lead to early recovery? Int J Pharm Chem Anal. 2020;7:149-150
  9. Wang J, Yang X, Li Y, Huang JA, Jiang J, Su N. Specific cytokines in the inflammatory cytokine storm of patients with COVID-19-associated acute respiratory distress syndrome and extrapulmonary multiple- organ dysfunction. Virol J. 2021;18:117
  10. Menzella F, Fontana M, Salvarani C, Massari M, Rug